Status:
RECRUITING
Patient Preferences on Same-day Bilateral Intravitreal Dexamethasone Injections
Lead Sponsor:
Rigshospitalet, Denmark
Conditions:
Informed Consent
Preference, Patient
Eligibility:
All Genders
18+ years
Brief Summary
Intravitreal injections with dexamethasone implant (Ozurdex®) provide a reasonable and long-lasting treatment option in the cases of diabetic macular edema, as well as macular edema resulting from ret...
Eligibility Criteria
Inclusion
- Inclusion criteria
- Having received at least one intravitreal dexamethasone implant in either eye
- \>18 years of age
- Capacity to comprehend and answer questions in Danish language
- Signed informed consent
- Exclusion criteria
- • No intravitreal dexamethasone implant received within the last 12 months
Exclusion
Key Trial Info
Start Date :
January 13 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2026
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06894017
Start Date
January 13 2025
End Date
January 1 2026
Last Update
July 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Ophthalmology, Rigshospitalet
Glostrup Municipality, Denmark, 2600